JPH09506770A - c−erbBの発現が関与する疾患を予防及び治療するためのアンチセンス核酸 - Google Patents
c−erbBの発現が関与する疾患を予防及び治療するためのアンチセンス核酸Info
- Publication number
- JPH09506770A JPH09506770A JP7517135A JP51713595A JPH09506770A JP H09506770 A JPH09506770 A JP H09506770A JP 7517135 A JP7517135 A JP 7517135A JP 51713595 A JP51713595 A JP 51713595A JP H09506770 A JPH09506770 A JP H09506770A
- Authority
- JP
- Japan
- Prior art keywords
- erbb
- nucleic acid
- nucleotide
- preventing
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.c-erbB-2をコードするメッセンジャーRNA(mRNA)及び/又は DNAのある領域 にハイブリダイズし、配列表中 Seq.ID No.1-105で規定された配列を含み、DN A- 又は RNA- 型構造を持ち、新生物、免疫疾患及び/又は異常脈管形成の関与 する疾患を治療又は予防することができるアンチセンス核酸又はその有効な誘導 体。 2.当該オリゴヌクレオチドがホスホロチオエート誘導体のような修飾されたオ リゴヌクレオチドである、請求項1に記載のアンチセンス オリゴヌクレオチド 。 3.固相に共有結合した最初のヌクレオチドに各ヌクレオチドが結合してヌクレ オチド鎖が 3'-5'方向に成長することによる亜リン酸トリエステル化学を用いた 固相合成によって得ることができ、この合成が以下の工程 − 先のヌクレオチドの 5'DMT保護基の開裂、 − 鎖を増殖させるための各ヌクレオチドの付加、 − 亜リン酸基の修飾、次いで未反応 5'-水酸基の封鎖、及び − 固体支持体からのオリゴヌクレオチドの開裂、 − それに続く合成生成物の処理 を含む、請求項1及び/又は2のいずれかに記載のアンチセンス核酸又はアン チセンス−オリゴヌクレオチド類。 4.新生物及び/又は免疫疾患及び/又は異常脈管形成の関与する疾患を予防及 び治療するための、請求項1〜3のいずれかに記載の化合物を有効量含む医薬用 組成物。 5.新生物及び/又は免疫疾患及び/又は異常脈管形成の関与する疾患を予防及 び治療するための医薬用組成物を製造するための、請求項1〜3のいずれかに記 載の化合物の使用。 6.請求項1〜3のいずれかに記載の化合物の診断薬としての使用。 7.請求項1〜3のいずれかに記載の化合物又は請求項4に記載の医薬用組成物 を c-erbB-2 の発現が関係する疾患の患者に有効量投与することにより、新生 物及び/又は免疫疾患及び異常脈管形成の関与する疾患を治療又は予防する方法 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93120710 | 1993-12-23 | ||
DE93120710.4 | 1993-12-23 | ||
PCT/EP1994/004094 WO1995017507A1 (en) | 1993-12-23 | 1994-12-09 | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09506770A true JPH09506770A (ja) | 1997-07-08 |
Family
ID=8213517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7517135A Pending JPH09506770A (ja) | 1993-12-23 | 1994-12-09 | c−erbBの発現が関与する疾患を予防及び治療するためのアンチセンス核酸 |
Country Status (7)
Country | Link |
---|---|
US (1) | US6365345B1 (ja) |
EP (1) | EP0736093B1 (ja) |
JP (1) | JPH09506770A (ja) |
AT (1) | ATE234919T1 (ja) |
AU (1) | AU1313095A (ja) |
DE (1) | DE69432315T2 (ja) |
WO (1) | WO1995017507A1 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5910583A (en) * | 1996-11-04 | 1999-06-08 | Duke University | Antisense oligonucleotides against ERBB-2 |
US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
KR100820266B1 (ko) | 1999-02-26 | 2008-04-08 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
ES2330301T3 (es) | 1999-08-27 | 2009-12-09 | Genentech, Inc. | Dosificaciones para tratamiento con anticuerpos anti-erbb2. |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
WO2001076630A1 (fr) * | 2000-04-06 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | Diagnostics et remedes contre la polyarthrite rhumatoide |
US6613567B1 (en) * | 2000-09-15 | 2003-09-02 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Her-2 expression |
CA2436910C (en) * | 2000-12-01 | 2014-06-17 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates |
AU2002248185A1 (en) * | 2000-12-14 | 2002-07-16 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
US20030124513A1 (en) * | 2001-05-29 | 2003-07-03 | Mcswiggen James | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV |
EP1430140B1 (en) * | 2001-08-01 | 2010-09-15 | University of Utah | N-terminally truncated isoforms of pde3a cyclic phosphodiesterases |
DE60322509D1 (de) * | 2002-01-17 | 2008-09-11 | Univ British Columbia | Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US20050287667A1 (en) * | 2004-06-01 | 2005-12-29 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
GB0417107D0 (en) * | 2004-07-30 | 2004-09-01 | Wellcome Trust The | Genes II |
WO2006056054A1 (en) * | 2004-11-23 | 2006-06-01 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
US7247457B2 (en) * | 2005-04-26 | 2007-07-24 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein |
JP5122474B2 (ja) * | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
CN103068983A (zh) | 2010-06-11 | 2013-04-24 | 安提森斯制药有限公司 | 用于选择性寡核苷酸修饰的方法 |
US9427458B2 (en) | 2010-07-22 | 2016-08-30 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet | Methods for inhibiting cancer cell proliferation |
KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1469292A (en) | 1991-01-18 | 1992-08-27 | Oncogene Science, Inc. | Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes |
FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
WO1993009788A1 (en) | 1991-11-13 | 1993-05-27 | Baylor College Of Medicine | Triplex forming oligonucleotide reagents targeted to the neu oncogene promoter and method of use |
US5599704A (en) * | 1992-08-26 | 1997-02-04 | Ribozyme Pharmaceuticals, Inc. | ErbB2/neu targeted ribozymes |
-
1994
- 1994-12-09 JP JP7517135A patent/JPH09506770A/ja active Pending
- 1994-12-09 US US08/666,341 patent/US6365345B1/en not_active Expired - Fee Related
- 1994-12-09 AU AU13130/95A patent/AU1313095A/en not_active Abandoned
- 1994-12-09 AT AT95904441T patent/ATE234919T1/de active
- 1994-12-09 WO PCT/EP1994/004094 patent/WO1995017507A1/en active IP Right Grant
- 1994-12-09 DE DE69432315T patent/DE69432315T2/de not_active Expired - Lifetime
- 1994-12-09 EP EP95904441A patent/EP0736093B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69432315D1 (de) | 2003-04-24 |
EP0736093B1 (en) | 2003-03-19 |
US6365345B1 (en) | 2002-04-02 |
ATE234919T1 (de) | 2003-04-15 |
DE69432315T2 (de) | 2004-02-12 |
AU1313095A (en) | 1995-07-10 |
EP0736093A1 (en) | 1996-10-09 |
WO1995017507A1 (en) | 1995-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09506770A (ja) | c−erbBの発現が関与する疾患を予防及び治療するためのアンチセンス核酸 | |
MacKellar et al. | Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups | |
JP4383720B2 (ja) | オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
AU750469B2 (en) | 2'-O-aminoethyloxyethyl-modified oligonucleotides | |
EP0552766B1 (de) | Oligonucleotidanaloga, deren Herstellung und Verwendung | |
EP0708829B1 (en) | A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms | |
RU2249458C2 (ru) | Олигонуклеотиды для ингибирования экспрессии eg5 человека | |
JPH07502749A (ja) | Rnaを調節するための組成物と方法 | |
IL185569A (en) | Cyclic acid and analogues of nucleotide nucleotides and oligonucleotides | |
JP2005522997A (ja) | 交代セグメントを含むオリゴヌクレオチド及びその用途 | |
US5908845A (en) | Polyether nucleic acids | |
CN110760516B (zh) | 核酸适配体衍生物和氨基化的核酸适配体衍生物以及它们的应用和药物偶合物 | |
JP2003505517A (ja) | 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用 | |
US5837856A (en) | Chirally enriched synthetic phosphonate oligomers | |
US6034234A (en) | Double-stranded oligonucleotide and anticancer agent containing the same as active ingredient | |
JP2007104971A (ja) | ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド | |
JP2002501505A (ja) | ヒトHa−ras遺伝子断片に相補的な修飾アンチセンスヌクレオチド | |
EP0747386A2 (en) | Method and antisense oligonucleotides to Interleukin-6 receptor mRNA for inhibiting cellular proliferation | |
WO1993015742A1 (en) | Oligonucleotides having zwitterionic moieties | |
US5716846A (en) | Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA | |
JP2003507037A (ja) | プロパンジオールを含有するキメラdna/rnaリボザイム | |
JP2022120380A (ja) | miRNA133-b誘導体及びその利用 | |
Allart et al. | 1, 5-Anhydro-2-deoxy-D-altritol oligonucleotides as conformationally restricted analogues of RNA | |
MXPA01000908A (en) | Short oligonucleotides for the inhibition of vegf expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050111 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050715 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050822 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060207 |